Catalent (NYSE:CTLT) Posts Earnings Results, Misses Expectations By $0.22 EPS

Catalent (NYSE:CTLTGet Free Report) posted its quarterly earnings results on Friday. The company reported ($0.24) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.02) by ($0.22), MarketWatch Earnings reports. The company had revenue of $1.03 billion during the quarter, compared to analyst estimates of $1.01 billion. Catalent had a positive return on equity of 1.55% and a negative net margin of 22.36%. The business’s revenue for the quarter was down 10.2% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.62 earnings per share.

Catalent Trading Up 0.3 %

Shares of NYSE:CTLT opened at $56.71 on Friday. Catalent has a one year low of $31.45 and a one year high of $74.49. The company has a 50 day moving average of $47.00 and a 200-day moving average of $44.80. The company has a current ratio of 1.70, a quick ratio of 1.19 and a debt-to-equity ratio of 1.13.

Institutional Investors Weigh In On Catalent

Several institutional investors have recently modified their holdings of the business. Barclays PLC grew its holdings in Catalent by 578.0% during the second quarter. Barclays PLC now owns 3,385,660 shares of the company’s stock valued at $146,802,000 after purchasing an additional 2,886,309 shares during the period. Norges Bank acquired a new position in shares of Catalent in the fourth quarter valued at approximately $65,774,000. Maverick Capital Ltd. acquired a new position in shares of Catalent in the fourth quarter valued at approximately $63,088,000. Morgan Stanley lifted its position in shares of Catalent by 113.3% in the fourth quarter. Morgan Stanley now owns 2,423,435 shares of the company’s stock worth $109,079,000 after purchasing an additional 1,287,018 shares in the last quarter. Finally, Ameriprise Financial Inc. lifted its position in shares of Catalent by 549.4% in the first quarter. Ameriprise Financial Inc. now owns 1,311,793 shares of the company’s stock worth $86,196,000 after purchasing an additional 1,109,802 shares in the last quarter.

Analyst Upgrades and Downgrades

Several research firms have issued reports on CTLT. StockNews.com upgraded shares of Catalent to a “sell” rating in a research report on Tuesday, February 6th. William Blair restated a “market perform” rating on shares of Catalent in a research report on Tuesday, November 14th. Barclays raised their price target on shares of Catalent from $45.00 to $47.00 and gave the stock an “equal weight” rating in a research report on Thursday, January 25th. Royal Bank of Canada reaffirmed a “sector perform” rating and set a $63.50 price objective (up from $58.00) on shares of Catalent in a report on Tuesday, February 6th. Finally, Wells Fargo & Company cut their price target on shares of Catalent from $50.00 to $42.00 and set an “equal weight” rating for the company in a report on Thursday, November 16th. Two investment analysts have rated the stock with a sell rating, nine have issued a hold rating and three have issued a buy rating to the company. According to data from MarketBeat.com, Catalent has a consensus rating of “Hold” and a consensus price target of $52.46.

Check Out Our Latest Stock Report on CTLT

Catalent Company Profile

(Get Free Report)

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.

Featured Articles

Earnings History for Catalent (NYSE:CTLT)

Receive News & Ratings for Catalent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent and related companies with MarketBeat.com's FREE daily email newsletter.